PH26230A - Antiarrhythmic method - Google Patents
Antiarrhythmic method Download PDFInfo
- Publication number
- PH26230A PH26230A PH39749A PH39749A PH26230A PH 26230 A PH26230 A PH 26230A PH 39749 A PH39749 A PH 39749A PH 39749 A PH39749 A PH 39749A PH 26230 A PH26230 A PH 26230A
- Authority
- PH
- Philippines
- Prior art keywords
- compound
- antiarrhythmic
- arrhythmia
- treatment
- formula
- Prior art date
Links
- 230000003288 anthiarrhythmic effect Effects 0.000 title description 12
- 238000000034 method Methods 0.000 title description 10
- 239000003416 antiarrhythmic agent Substances 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 description 30
- 206010003119 arrhythmia Diseases 0.000 description 27
- HZIWGOAXOBPQGY-UHFFFAOYSA-N LY201116 Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC=C(N)C=C1 HZIWGOAXOBPQGY-UHFFFAOYSA-N 0.000 description 20
- 230000006793 arrhythmia Effects 0.000 description 20
- 241000124008 Mammalia Species 0.000 description 14
- 238000011282 treatment Methods 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- 230000036982 action potential Effects 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 8
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 7
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 7
- 244000166550 Strophanthus gratus Species 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 7
- 229960003343 ouabain Drugs 0.000 description 7
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 7
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229960002036 phenytoin Drugs 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 229960001412 pentobarbital Drugs 0.000 description 4
- 230000002336 repolarization Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 210000003742 purkinje fiber Anatomy 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 208000003663 ventricular fibrillation Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ZSXGPMMRFFQFCH-UHFFFAOYSA-N 4-amino-n-(2,6-dimethylphenyl)-3,5-dimethylbenzamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(C)=C(N)C(C)=C1 ZSXGPMMRFFQFCH-UHFFFAOYSA-N 0.000 description 1
- -1 9,9-disubstituted fluorenes Chemical class 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001527806 Iti Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960002624 bretylium tosilate Drugs 0.000 description 1
- KVWNWTZZBKCOPM-UHFFFAOYSA-M bretylium tosylate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CC[N+](C)(C)CC1=CC=CC=C1Br KVWNWTZZBKCOPM-UHFFFAOYSA-M 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- UVLGBYAOIKKOOQ-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-3,5-dimethylbenzamide Chemical compound CC1=CC(C)=CC(C(=O)NC=2C(=CC=CC=2C)C)=C1 UVLGBYAOIKKOOQ-UHFFFAOYSA-N 0.000 description 1
- QIFYWJGCNCSYNT-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NC=2C(=CC=CC=2C)C)=C1 QIFYWJGCNCSYNT-UHFFFAOYSA-N 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036390 resting membrane potential Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/290,675 US4931470A (en) | 1988-12-27 | 1988-12-27 | Antiarrhythmic method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26230A true PH26230A (en) | 1992-04-01 |
Family
ID=23117079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH39749A PH26230A (en) | 1988-12-27 | 1989-12-20 | Antiarrhythmic method |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4931470A (da) |
| EP (1) | EP0376608A3 (da) |
| JP (1) | JPH02215712A (da) |
| KR (1) | KR900009070A (da) |
| AU (1) | AU617024B2 (da) |
| CA (1) | CA2006500A1 (da) |
| DK (1) | DK652989A (da) |
| HU (1) | HU203196B (da) |
| PH (1) | PH26230A (da) |
| ZA (1) | ZA899793B (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2164512C1 (ru) * | 1999-07-27 | 2001-03-27 | Всероссийский научный центр по безопасности биологически активных веществ | Производные аминокислот, проявляющие антиаритмическую активность |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4004029A (en) * | 1974-05-13 | 1977-01-18 | The Upjohn Company | Compositions and method for treating epilepsy and convulsions |
| US4073940A (en) * | 1976-10-28 | 1978-02-14 | Centre Europeen De Recherches Pharmacologiques C.E.R.P.H.A. | Method for treating cardiac arhythmia by administration of basic aryloxyacetamide |
| US4555525A (en) * | 1984-08-31 | 1985-11-26 | Administrators Of The Tulane Educational Fund | Use of desethyl-N-acetylprocainamide (NAPADE) as an inotropic agent |
| US4684748A (en) * | 1985-07-26 | 1987-08-04 | Eli Lilly And Company | Anticonvulsant agents |
| US4638014A (en) * | 1985-08-26 | 1987-01-20 | Research Corporation | Anticonvulsant method and formulations |
-
1988
- 1988-12-27 US US07/290,675 patent/US4931470A/en not_active Expired - Fee Related
-
1989
- 1989-12-20 AU AU47191/89A patent/AU617024B2/en not_active Ceased
- 1989-12-20 ZA ZA899793A patent/ZA899793B/xx unknown
- 1989-12-20 PH PH39749A patent/PH26230A/en unknown
- 1989-12-20 HU HU896703A patent/HU203196B/hu not_active IP Right Cessation
- 1989-12-20 EP EP19890313372 patent/EP0376608A3/en not_active Withdrawn
- 1989-12-20 KR KR1019890018969A patent/KR900009070A/ko not_active Withdrawn
- 1989-12-21 DK DK652989A patent/DK652989A/da not_active Application Discontinuation
- 1989-12-22 CA CA002006500A patent/CA2006500A1/en not_active Abandoned
- 1989-12-22 JP JP1334677A patent/JPH02215712A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HU896703D0 (en) | 1990-02-28 |
| HU203196B (en) | 1991-06-28 |
| JPH02215712A (ja) | 1990-08-28 |
| DK652989D0 (da) | 1989-12-21 |
| CA2006500A1 (en) | 1990-06-27 |
| KR900009070A (ko) | 1990-07-02 |
| ZA899793B (en) | 1991-08-28 |
| DK652989A (da) | 1990-06-28 |
| AU4719189A (en) | 1990-07-05 |
| AU617024B2 (en) | 1991-11-14 |
| US4931470A (en) | 1990-06-05 |
| EP0376608A3 (en) | 1991-03-13 |
| HUT52371A (en) | 1990-07-28 |
| EP0376608A2 (en) | 1990-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Neuvonen et al. | Prolonged QT interval and severe tachyarrhythmias, common features of sotalol intoxication | |
| US4470965A (en) | Celiprolol for the treatment of glaucoma | |
| Gaita et al. | Stress and pharmacologic tests as methods to identify patients with Wolff-Parkinson-White syndrome at risk of sudden death | |
| Johnsson et al. | Haemodynamic and tolerance studies in man of a new, orally active, selective β 1-adrenoceptor agonist H 80/62 | |
| Farmer et al. | A comparison of some cardiovascular properties of propranolol, MJ 1999 and quinidine in relation to their effects in hypertensive animals | |
| Ward et al. | The acute cardiac electrophysiological effects of intravenous sotalol hydrochloride | |
| US4562196A (en) | 2,4-Diaminopyridine as a pharmacologic agent | |
| US4147804A (en) | Amidinourea local anesthetics | |
| Williams et al. | Cardiospecificity of (β-receptor blockade: A comparison of the relative potencies on cardiac and peripheral vascular (β-adrenoceptors of propranolol, of practolol and its ortho-substituted isomer, and of oxprenolol and its para-substituted isomer | |
| US4178387A (en) | Method for the treatment of arrhythmia | |
| Gould et al. | Treatment of cardiac arrhythmias with phentolamine | |
| US4931470A (en) | Antiarrhythmic method | |
| Wasserman et al. | Cardiovascular and bronchomotor responses to selective beta adrenergic receptor agonists in the anesthetized dog | |
| Thomson et al. | The pharmacokinetics of R‐and S‐tocainide in patients with acute ventricular arrhythmias. | |
| Warner | Beta-adrenergic blocking agents and anaesthesia: a review | |
| US3983249A (en) | Method for treating angina pectoris with certain N-arylsulfonyl-N'(aza-3-bicycloalkyl) ureas | |
| Segal et al. | Coronary spasm produced by picrotoxin in cats | |
| HU190355B (en) | Process for producing pharmaceutical compositions for treating coronaria-diseases and hypertonia | |
| FREDERICK et al. | Cardiovascular profile of a new anti-arrhythmic agent, SC-40230 | |
| US4061756A (en) | Methods for treating cardiovascular disorders | |
| Yoshimura | The relation of tooth extraction to anginal attack | |
| US3840666A (en) | Anti-arrhythmic quaternary salt compositions and methods of use | |
| SMITH et al. | Succinylcholine, digitalis, and hypercalcemia: a case report | |
| Rashid et al. | Cardiovascular actions of meptazinol in comparison with pentazocine and morphine | |
| LeWINTER et al. | Effects of oral equiblocking doses of a cardioselective and noncardioselective β-adrenergic blocking agent on left ventricular function in the normal conscious dog |